New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...

Ethosuximide, a T-type calcium channel blocker, demonstrated no significant benefit as a treatment for patients with irritable bowel syndrome-related abdominal pain, according to results of a proof-of ...

Please provide your email address to receive an email when new articles are posted on . Beta-blockers more effectively reduce risk for death or hospitalization in people with HFpEF compared with ...

New research has identified the specific biological mechanism behind the muscle dysfunction found in myotonic dystrophy type 1 (DM1) and further shows that calcium channel blockers can reverse these ...

Myotonic dystrophy is one of the most common forms of muscular dystrophy. It is a genetic condition that causes progressive muscle weakness and wasting. No treatments currently exist that slow the ...

Praxis Precision Medicines' ulixacaltamide (PRAX-944) is a potent and selective small molecule T-type Ca2+ channel blocker being developed for the potential treatment of essential tremor. ET is a ...

Hand opening pill bottle Clearer guidelines for diuretic management in patients with chronic kidney disease are needed, according to investigators. Adding diuretics rather than calcium channel ...

Findings provide reassurance to physicians and patients about the long-term safety of dihydropyridine calcium channel blockers in the treatment of pancreatic cancer. This was a new user, active ...

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 23, entitled, “Benidipine calcium channel blocker ...

A woman with hopes to conceive was diagnosed with severe vasospastic angina (VSA); however, she was able to carry a healthy baby to full term without angina attacks after starting treatment of a ...

NEW YORK, July 31 (Praxis Press) Cardiovascular outcomes have not been compared in hypertensive patients treated with calcium channel blockers and in patients treated with older drugs. Hansson and ...